Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.
<h4>Background</h4>Gliosarcoma is one of the most common malignant brain tumors, and anti-angiogenesis is a promising approach for the treatment of gliosarcoma. However, chemotherapy is obstructed by the physical obstacle formed by the blood-brain barrier (BBB) and blood-cerebrospinal fl...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/dece1e78bedd4ac4bc8ff29f1753f881 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:dece1e78bedd4ac4bc8ff29f1753f881 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:dece1e78bedd4ac4bc8ff29f1753f8812021-11-18T06:54:38ZHonokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.1932-620310.1371/journal.pone.0018490https://doaj.org/article/dece1e78bedd4ac4bc8ff29f1753f8812011-04-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21559510/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Gliosarcoma is one of the most common malignant brain tumors, and anti-angiogenesis is a promising approach for the treatment of gliosarcoma. However, chemotherapy is obstructed by the physical obstacle formed by the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Honokiol has been known to possess potent activities in the central nervous system diseases, and anti-angiogenic and anti-tumor properties. Here, we hypothesized that honokiol could cross the BBB and BCSFB for the treatment of gliosarcoma.<h4>Methodologies</h4>We first evaluated the abilities of honokiol to cross the BBB and BCSFB by measuring the penetration of honokiol into brain and blood-cerebrospinal fluid, and compared the honokiol amount taken up by brain with that by other tissues. Then we investigated the effect of honokiol on the growth inhibition of rat 9L gliosarcoma cells and human U251 glioma cells in vitro. Finally we established rat 9L intracerebral gliosarcoma model in Fisher 344 rats and human U251 xenograft glioma model in nude mice to investigate the anti-tumor activity.<h4>Principal findings</h4>We showed for the first time that honokiol could effectively cross BBB and BCSFB. The ratios of brain/plasma concentration were respectively 1.29, 2.54, 2.56 and 2.72 at 5, 30, 60 and 120 min. And about 10% of honokiol in plasma crossed BCSFB into cerebrospinal fluid (CSF). In vitro, honokiol produced dose-dependent inhibition of the growth of rat 9L gliosarcoma cells and human U251 glioma cells with IC(50) of 15.61 µg/mL and 16.38 µg/mL, respectively. In vivo, treatment with 20 mg/kg body weight of honokiol (honokiol was given twice per week for 3 weeks by intravenous injection) resulted in significant reduction of tumor volume (112.70±10.16 mm(3)) compared with vehicle group (238.63±19.69 mm(3), P = 0.000), with 52.77% inhibiting rate in rat 9L intracerebral gliosarcoma model, and (1450.83±348.36 mm(3)) compared with vehicle group (2914.17±780.52 mm(3), P = 0.002), with 50.21% inhibiting rate in human U251 xenograft glioma model. Honokiol also significantly improved the survival over vehicle group in the two models (P<0.05).<h4>Conclusions/significance</h4>This study provided the first evidence that honokiol could effectively cross BBB and BCSFB and inhibit brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. It suggested a significant strategy for offering a potential new therapy for the treatment of gliosarcoma.Xianhuo WangXingmei DuanGuangli YangXiaoyan ZhangLinyu DengHao ZhengChongyang DengJiaolin WenNing WangCheng PengXia ZhaoYuquan WeiLijuan ChenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 4, p e18490 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Xianhuo Wang Xingmei Duan Guangli Yang Xiaoyan Zhang Linyu Deng Hao Zheng Chongyang Deng Jiaolin Wen Ning Wang Cheng Peng Xia Zhao Yuquan Wei Lijuan Chen Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. |
| description |
<h4>Background</h4>Gliosarcoma is one of the most common malignant brain tumors, and anti-angiogenesis is a promising approach for the treatment of gliosarcoma. However, chemotherapy is obstructed by the physical obstacle formed by the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Honokiol has been known to possess potent activities in the central nervous system diseases, and anti-angiogenic and anti-tumor properties. Here, we hypothesized that honokiol could cross the BBB and BCSFB for the treatment of gliosarcoma.<h4>Methodologies</h4>We first evaluated the abilities of honokiol to cross the BBB and BCSFB by measuring the penetration of honokiol into brain and blood-cerebrospinal fluid, and compared the honokiol amount taken up by brain with that by other tissues. Then we investigated the effect of honokiol on the growth inhibition of rat 9L gliosarcoma cells and human U251 glioma cells in vitro. Finally we established rat 9L intracerebral gliosarcoma model in Fisher 344 rats and human U251 xenograft glioma model in nude mice to investigate the anti-tumor activity.<h4>Principal findings</h4>We showed for the first time that honokiol could effectively cross BBB and BCSFB. The ratios of brain/plasma concentration were respectively 1.29, 2.54, 2.56 and 2.72 at 5, 30, 60 and 120 min. And about 10% of honokiol in plasma crossed BCSFB into cerebrospinal fluid (CSF). In vitro, honokiol produced dose-dependent inhibition of the growth of rat 9L gliosarcoma cells and human U251 glioma cells with IC(50) of 15.61 µg/mL and 16.38 µg/mL, respectively. In vivo, treatment with 20 mg/kg body weight of honokiol (honokiol was given twice per week for 3 weeks by intravenous injection) resulted in significant reduction of tumor volume (112.70±10.16 mm(3)) compared with vehicle group (238.63±19.69 mm(3), P = 0.000), with 52.77% inhibiting rate in rat 9L intracerebral gliosarcoma model, and (1450.83±348.36 mm(3)) compared with vehicle group (2914.17±780.52 mm(3), P = 0.002), with 50.21% inhibiting rate in human U251 xenograft glioma model. Honokiol also significantly improved the survival over vehicle group in the two models (P<0.05).<h4>Conclusions/significance</h4>This study provided the first evidence that honokiol could effectively cross BBB and BCSFB and inhibit brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. It suggested a significant strategy for offering a potential new therapy for the treatment of gliosarcoma. |
| format |
article |
| author |
Xianhuo Wang Xingmei Duan Guangli Yang Xiaoyan Zhang Linyu Deng Hao Zheng Chongyang Deng Jiaolin Wen Ning Wang Cheng Peng Xia Zhao Yuquan Wei Lijuan Chen |
| author_facet |
Xianhuo Wang Xingmei Duan Guangli Yang Xiaoyan Zhang Linyu Deng Hao Zheng Chongyang Deng Jiaolin Wen Ning Wang Cheng Peng Xia Zhao Yuquan Wei Lijuan Chen |
| author_sort |
Xianhuo Wang |
| title |
Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. |
| title_short |
Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. |
| title_full |
Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. |
| title_fullStr |
Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. |
| title_full_unstemmed |
Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. |
| title_sort |
honokiol crosses bbb and bcsfb, and inhibits brain tumor growth in rat 9l intracerebral gliosarcoma model and human u251 xenograft glioma model. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2011 |
| url |
https://doaj.org/article/dece1e78bedd4ac4bc8ff29f1753f881 |
| work_keys_str_mv |
AT xianhuowang honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT xingmeiduan honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT guangliyang honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT xiaoyanzhang honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT linyudeng honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT haozheng honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT chongyangdeng honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT jiaolinwen honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT ningwang honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT chengpeng honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT xiazhao honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT yuquanwei honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel AT lijuanchen honokiolcrossesbbbandbcsfbandinhibitsbraintumorgrowthinrat9lintracerebralgliosarcomamodelandhumanu251xenograftgliomamodel |
| _version_ |
1718424261098471424 |